Camus C, Charasse C, Jouannic-Montier I, Seguin P, Tulzo Y L, Bouget J, Thomas R
Service de Reanimation Medicale, Hopital Pontchaillou, Rennes, France.
Intensive Care Med. 1996 Feb;22(2):116-21. doi: 10.1007/BF01720717.
To assess the efficacy, adverse effects and relevance of calcium-free hemodialysis (CFHD) in the treatment of major hypercalcemia.
Retrospective chart review.
Medical ICU.
All patients admitted over a 9-year period for hypercalcemia requiring urgent treatment and who underwent hemodialysis.
CFHD with an acetate dialysate.
Thirty-three patients with severe hypercalcemia from various etiologies received CFHD. Marked and rapid decrease of serum total calcium was obtained during all sessions (mean decrease: 1.71 +/- 0.54 mmol/l). Calcium rebound within 24 h after CFHD was observed in all evaluable cases (1 +/- 0.45 mmol/l; mean delay 13.7 +/- 5.8 h). Adverse cardiovascular effects occurred in 17 of 48 sessions (35%) and in 13 of 30 evaluable patients (43%).
Adverse effects are frequent during CFHD. After correction of hypovolemia, its use should be restricted to patients with severe clinical symptoms or advanced renal impairment.
评估无钙血液透析(CFHD)治疗重度高钙血症的疗效、不良反应及相关性。
回顾性病历审查。
内科重症监护病房。
9年间因高钙血症需紧急治疗且接受血液透析的所有患者。
使用醋酸盐透析液进行CFHD。
33例各种病因导致的重度高钙血症患者接受了CFHD。所有透析过程中血清总钙均显著快速下降(平均下降:1.71±0.54 mmol/L)。所有可评估病例在CFHD后24小时内均观察到钙反弹(1±0.45 mmol/L;平均延迟13.7±5.8小时)。48次透析中有17次(35%)出现不良心血管效应,30例可评估患者中有13例(43%)出现。
CFHD期间不良反应频繁。纠正血容量不足后,其使用应仅限于有严重临床症状或晚期肾功能损害的患者。